NCT03912948 (DCPO Sein) is a clinical trial in Surgery, sponsored by Institut Claudius Regaud.

Who is sponsoring NCT03912948?

NCT03912948 is sponsored by Institut Claudius Regaud.

What condition does NCT03912948 study?

NCT03912948 studies Surgery, Breast Cancer, Pain, Postoperative, Pain, Chronic.

Is NCT03912948 still recruiting?

NCT03912948 is currently completed. Last updated 4 March 2020.

Last reviewed 2020-03-04 · How we verify

NCT03912948: DCPO Sein

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic Pain and Minor Breast Cancer Surgery

Completed Last updated 4 March 2020

What this trial tests

trial in Surgery in 205 participants. Completed in 31 December 2019.

Timeline

1 April 2019

Primary endpoint
30 September 2019

31 December 2019

Quick facts

Lead sponsor	Institut Claudius Regaud
Status	Completed
Study type	OBSERVATIONAL
Enrollment	205
Start date	1 April 2019
Primary completion	30 September 2019
Estimated completion	31 December 2019
Sites	1 location across France

Conditions studied

Surgery — all drugs for Surgery →
Breast Cancer — all drugs for Breast Cancer →
Pain, Postoperative — all drugs for Pain, Postoperative →
Pain, Chronic — all drugs for Pain, Chronic →

Sponsor

Institut Claudius Regaud — full company profile →

Who can join

18 and older, female only, with Surgery or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Breast cancer is the most frequent in women. Early diagnosis and recent treatments have improved overall mortality. However, chronic pain (pain lasting more than 3 months after surgery) remains a public health problem with impact on quality of life for these patients. The incidence of pain has been reported up to 25 to 60% of patients in the literature, even many years after a radical mastectomy. The neuropathic component of the pain is usually underestimated. In a prospective cohort study we have demonstrated that 43% of patient needed on average 5mg of morphine intravenously in the recovery room after a conservative breast cancer surgery, despite a multimodal regimen of analgesic drugs. In the same study, 40% of patients reported persistent pain 3 months after the surgery. To improve the analgesia in such a population, we decided to introduce regional analgesia technique (serratus block) systematically. This became our gold standard in our daily practice. We would like to assess the efficacy of such regional analgesia techniques on opioids consumption in the recovery room and the incidence of pain 3 months after conservative breast cancer surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Surgery

Currently open trials in the same condition.

NCT07369921 — Pediatric Pilonidal Sinus Surgical Treatment · NA · recruiting
NCT07362303 — Neuralert Stroke Monitor Trial · NA · recruiting
NCT07404163 — Walkway Used in Postoperative Mobilization · NA · active not recruiting
NCT07218289 — Green Light for Post-Operative Wellness · NA · recruiting
NCT07342751 — The Effect of Listening to Music During Mobilization on Pain and Fear in Children Undergoing Abdominal Surgery · NA · active not recruiting

Other Institut Claudius Regaud trials

Trials by the same sponsor.

NCT07427186 — Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage · NA · not yet recruiting
NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting
NCT06797037 — Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Pat · NA · recruiting
NCT06408038 — Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03912948 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Claudius Regaud
Last refreshed: 4 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03912948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing